Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; magnesium stearate; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cladribine, quantity: 10 mg - tablet, uncoated - excipient ingredients: hydroxypropylbetadex; sorbitol; magnesium stearate - mavenclad is indicated for the treatment of relapsing-remitting multiple sclerosis (rrms) to reduce the frequency of clinical relapses and to delay the progression of physical disability.,following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. re-initiation of therapy after year 4 has not been studied.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: copovidone; simethicone; purified talc; glyceryl monostearate; stearic acid; polysorbate 80; titanium dioxide; colloidal anhydrous silica; propylene glycol; macrogol 6000; hypromellose; microcrystalline cellulose; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; crospovidone; iron oxide red; sucrose; hydrolysed maize starch; maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; propylene glycol; simethicone; stearic acid; macrogol 6000; crospovidone; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; copovidone; polysorbate 80; hypromellose; purified talc; povidone; iron oxide red; maize starch; sucrose; hydrolysed maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - . short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesphagitis. the intravenous injection is indicated where oral treatment is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - hydrochlorothiazide, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; sunset yellow fcf aluminium lake - hypertension: may be used alone or in combination with other antihypertensive drugs. oedema: associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure (see precautions), premenstrual tension, and drug induced oedema.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - carbimazole, quantity: 5 mg - tablet, multilayer - excipient ingredients: lactose monohydrate; sucrose; acacia; maize starch; purified talc; magnesium stearate; gelatin; iron oxide red - therapy of hyperthyroidism. definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. preparation for thyroidectomy. before and after radioactive iodine treatment.

Israel - English - Ministry of Health

taro international ltd, israel - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophgeal reflux disease (gerd)in combination with antibiotics in treatment of duodenal ulcer caused by helicobactor pylori